Nutritional support for patients with moderate-to-advanced AMD

Article

Scientific studies show that the inclusion of high levels of omega-3 fatty acids, lutein and zeaxanthin in the diet supports eye health.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Early intervention is crucial for long-term outcomes in paediatric gene therapy
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Robert Ang, MD, explains why a small-aperture IOL is "not a niche product"
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Sheng Lim, MD, FRCOphth, brings data from the CONCEPT study to the ASCRS meeting
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
How embracing opposition sends clinicians home from COPHy with more useful takeaways
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Angiogenesis 2025: The global forecast for AI-driven home OCT
Related Content
An older man with glasses sits in a wheelchair. Concept image for cabozantinib and corneal perforation, ocular adverse effects, vascular endothelial growth factor VEGF tyrosine kinase inhibitor TKI. Image credit: ©Photographee.eu – stock.adobe.com

Case report examines corneal perforation associated with tyrosine kinase inhibitor

Lynda Charters
June 10th 2025
Article

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Marc Labetoulle, MD, PhD, and the logo for the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal, 7 to 9 June, 2025. Concept image for SOE presentation, poster presentation on dry eye research. Includes the email soe.2025@soevision.org

New dry eye disease study compares two preservative-free artificial tear drops

Hattie Hayes;Marc Labetoulle, MD, PhD
June 7th 2025
Article

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

The Belém Tower (Torre de Belém) in Lisbon, Portugal. Concept image for ophthalmology conference, European Society of Ophthalmology SOE Congress 2025 meeting program and schedule. Image credit: ©PhotosbyPatrick – stock.adobe.com

Keynote lectures and YO sessions at the 2025 SOE Congress

Hattie Hayes
June 7th 2025
Article

Special programming for young ophthalmologists will be hosted in the YO lounge

A trolley train car in Lisbon, Portugal. Concept image for the European Society of Ophthalmology SOE meeting in Lisbon, historic Belem, Tagus River. Conference agenda schedule and meeting information. Image credit: ©smallredgirl – stock.adobe.com

The European Society of Ophthalmology (SOE) meeting kicks off in Lisbon, Portugal

Hattie Hayes
June 6th 2025
Article

This year’s multi-specialty programme features the SOE Leadership Development Programme (EuLDP), the International Society of Ocular Trauma (ISOT), European University Professors of Ophthalmology (EUPO) and more

The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 5th 2025
Article

The biopharmaceutical is the first biosimilar to ranibizumab (Genentech Inc.) approved in Brazil

© 2025 MJH Life Sciences

All rights reserved.